CN112245587B - 含nad和胆碱酯酶抑制剂的药物组合物及其用途 - Google Patents
含nad和胆碱酯酶抑制剂的药物组合物及其用途 Download PDFInfo
- Publication number
- CN112245587B CN112245587B CN202011125738.2A CN202011125738A CN112245587B CN 112245587 B CN112245587 B CN 112245587B CN 202011125738 A CN202011125738 A CN 202011125738A CN 112245587 B CN112245587 B CN 112245587B
- Authority
- CN
- China
- Prior art keywords
- nad
- pharmaceutical composition
- rivastigmine
- galantamine
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims abstract description 29
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims abstract description 66
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims abstract description 34
- 229960004136 rivastigmine Drugs 0.000 claims abstract description 34
- 229960003980 galantamine Drugs 0.000 claims abstract description 33
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims abstract description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 8
- 239000008297 liquid dosage form Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008299 semisolid dosage form Substances 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract description 49
- 229960003530 donepezil Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 23
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 74
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 74
- 229950006238 nadide Drugs 0.000 description 72
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 45
- 229940079593 drug Drugs 0.000 description 23
- 239000001963 growth medium Substances 0.000 description 14
- 239000011148 porous material Substances 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000007747 plating Methods 0.000 description 6
- 239000004017 serum-free culture medium Substances 0.000 description 6
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 5
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 4
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 4
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 3
- 108010041191 Sirtuin 1 Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000007370 cognitive improvement Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007450 amyloidogenic pathway Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000010326 executive functioning Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011125738.2A CN112245587B (zh) | 2020-10-20 | 2020-10-20 | 含nad和胆碱酯酶抑制剂的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011125738.2A CN112245587B (zh) | 2020-10-20 | 2020-10-20 | 含nad和胆碱酯酶抑制剂的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112245587A CN112245587A (zh) | 2021-01-22 |
CN112245587B true CN112245587B (zh) | 2022-02-22 |
Family
ID=74245531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011125738.2A Active CN112245587B (zh) | 2020-10-20 | 2020-10-20 | 含nad和胆碱酯酶抑制剂的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112245587B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306366B (zh) * | 2021-11-30 | 2023-01-06 | 合肥康诺生物制药有限公司 | 含nad和cd38抑制剂的药物组合物及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020081923A1 (en) * | 2018-10-19 | 2020-04-23 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
-
2020
- 2020-10-20 CN CN202011125738.2A patent/CN112245587B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020081923A1 (en) * | 2018-10-19 | 2020-04-23 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
Non-Patent Citations (3)
Title |
---|
电针并药物治疗面神经炎疗效观察;王少贞;《针灸临床杂志》;20130920;第29卷(第9期);13-15 * |
闭塞性脑血管病24例;张树田;《实用儿科临床杂志》;19950510;第10卷(第3期);155-156 * |
阿尔茨海默病相关治疗的研究进展;毕祥云;等;《中华保健医学杂志》;20170630;第19卷(第3期);275-277页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112245587A (zh) | 2021-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6083932A (en) | Pharmaceutical compositions derived from ginseng and methods of treatment using same | |
Patris et al. | Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice | |
Liu et al. | Microglia Polarization from M1 toward M2 Phenotype Is Promoted by Astragalus Polysaccharides Mediated through Inhibition of miR‐155 in Experimental Autoimmune Encephalomyelitis | |
CN113143946A (zh) | 烟酰胺单核苷酸及其在抗肿瘤药物心肌损伤中的保护应用 | |
Liu et al. | Inhibition of TRPA1 Ameliorates Periodontitis by Reducing Periodontal Ligament Cell Oxidative Stress and Apoptosis via PERK/eIF2α/ATF‐4/CHOP Signal Pathway | |
CN112245587B (zh) | 含nad和胆碱酯酶抑制剂的药物组合物及其用途 | |
WO2015140799A1 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
EP4205732A1 (en) | Cannabinoid composition and application thereof in preparation of drug for treating neurodegenerative diseases such as parkinson's disease and alzheimer's disease | |
US20240122873A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
AU2010258821A1 (en) | Genotype specific methods for treating human subjects using 4- methylpyrazole | |
CN102755341A (zh) | 类叶升麻苷在制备防治阿尔茨海默病药物中的用途 | |
CN103860575A (zh) | 京尼平苷作为乙酰胆碱酯酶抑制剂的应用 | |
CN111569080A (zh) | Plga在制备ssri类抗抑郁药物微球中的应用 | |
CN103191407A (zh) | 一种五肽及其代谢物用于制备抗痴呆产品的新用途 | |
CN112245588A (zh) | 含nad和nmda受体拮抗剂的药物组合物及其用途 | |
CN113244255A (zh) | 灯盏花素作为化疗药物心肌毒性预防和治疗药物的应用 | |
CN1695604A (zh) | 防治神经退行疾病、注意力缺陷多动症和抑郁症的药物 | |
CN109528719B (zh) | 长春西汀在制备预防和/或治疗急进高原导致的高原病的药物中的应用 | |
EP2556833B1 (en) | Pharmaceutical composition for the treatment of alzheimer's disease, method for producing same and use thereof | |
CN115919841B (zh) | 一种用于预防或治疗阿尔茨海默病的中药单体组合物及应用 | |
WO2019124601A1 (ko) | NFAT5 및 NF-kB의 결합 억제제를 유효성분으로 포함하는 백내장 예방 또는 치료용 조성물 | |
Kashio et al. | Taurine, Coenzyme Q10, and Hydrogen Water Prevents Germanium Dioxide-Induced Mitochondrial Dysfunction and Associated Sensorineural Hearing Loss in mouse | |
Ussipbek et al. | Prospects of the application of coenzyme Q10 for correction of mitochondrial dysfunction | |
CN108159035A (zh) | 肉桂酸类衍生物的新用途 | |
CN110251494B (zh) | 2,7,2′-三羟基-4,4′,7′-三甲氧基-1,1′-双菲的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 231100 southeast corner of the intersection of Huainan North Road and Huaihai Avenue, Changfeng Shuangfeng Economic Development Zone, Hefei City, Anhui Province Patentee after: Hefei Kangnuo Biopharmaceutical Co.,Ltd. Patentee after: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Address before: 231100 southeast corner of the intersection of Huainan North Road and Huaihai Avenue, Changfeng Shuangfeng Economic Development Zone, Hefei City, Anhui Province Patentee before: Hefei Kangnuo biopharmaceutical Co.,Ltd. Patentee before: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 231100 southeast corner of the intersection of Huainan North Road and Huaihai Avenue, Changfeng Shuangfeng Economic Development Zone, Hefei City, Anhui Province Patentee after: Kangnuo Biopharmaceutical Co.,Ltd. Patentee after: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Address before: 231100 southeast corner of the intersection of Huainan North Road and Huaihai Avenue, Changfeng Shuangfeng Economic Development Zone, Hefei City, Anhui Province Patentee before: Hefei Kangnuo Biopharmaceutical Co.,Ltd. Patentee before: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. |